CARLOS JAVIER
ANGUITA VELASCO
Profesor asociado de Ciencias de la Salud
Publicacions (58) Publicacions de CARLOS JAVIER ANGUITA VELASCO
2024
-
Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy
Blood transfusion = Trasfusione del sangue, Vol. 22, Núm. 3, pp. 239-245
-
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients
Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12
-
Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial
Vox Sanguinis, Vol. 119, Núm. 1, pp. 27-33
-
Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantation
Frontiers in Immunology, Vol. 15
2023
-
Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide
Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567
-
Red Blood Cell Transfusion after Postpartum Hemorrhage: Clinical Variables Associated with Lack of Postpartum Hemorrhage Etiology Identification
Journal of Clinical Medicine, Vol. 12, Núm. 19
-
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
Frontiers in immunology, Vol. 14, pp. 1165759
2022
-
Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy
Transfusion, Vol. 62, Núm. 10, pp. 2143-2147
-
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
Frontiers in immunology, Vol. 13, pp. 1002959
-
Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide
Transfusion, Vol. 62, Núm. 2, pp. 374-385
-
FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 16
-
Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility
International Journal of Hematology, Vol. 115, Núm. 1, pp. 61-68
2021
-
Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide
Frontiers in Immunology, Vol. 12
-
Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre
Blood transfusion = Trasfusione del sangue, Vol. 19, Núm. 4, pp. 292-299
-
Elafin as a Predictive Biomarker of Acute Skin Graft-Versus-Host Disease After Haploidentical Stem Cell Transplantation Using Post-Transplant High-Dose Cyclophosphamide
Frontiers in Immunology, Vol. 12
-
Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia
Leukemia and Lymphoma, Vol. 62, Núm. 5, pp. 1178-1186
-
International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses
Vox Sanguinis, Vol. 116, Núm. 5, pp. e25-e43
-
Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant
Frontiers in Immunology, Vol. 12
-
Next generation cytogenetics in myeloid hematological neoplasms: Detection of cnvs and translocations
Cancers, Vol. 13, Núm. 12
-
Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation
Annals of Hematology, Vol. 100, Núm. 2, pp. 541-553